Articles & Video
The Future of the Oligonucleotide and Peptide Therapeutics Industry
What changes could happen in the oligonucleotide and peptide therapeutics industry over the next decade? This interactive ebook gathers predictions from industry professionals all over the globe.
Emerging Therapies Content Library: Whitepapers and Reports Collection
Explore our collection of exclusive whitepapers and reports covering the most exciting developments in emerging therapies with one simple registration.
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Diversity and Inclusion in Biotech
The life science industry has a challenge to become more equal, diverse and inclusive. Join us at Diversity and Inclusion in Biotech, September 22nd and find out how TOGETHER we can make a difference.
SURVEY: Partnering and Deal-Making in Biopharma through the Pandemic
We are conducting a huge study to gauge perspectives around biopharma deal-making during COVID-19 and the commercial ramifications of the pandemic. Take part here.
42% of pharma industry believe cell and gene therapies to be most promising therapeutics
According to a recent study, 42% of pharma industry professionals predict cell and gene therapies are the therapeutic area that will see the fastest growth in the next 10 years.
Peptide Therapies — Small Biomolecules Address Big Health Problems
This BioProcess International ebook looks at product research, manufacturing and regulatory concerns within the promising world of peptide therapies.
Oligonucleotides and peptides: the regulatory challenges
We investigate where current regulatory obstacles lie surrounding peptide and oligonucleotide therapeutics.
80% of life sciences professionals predict a COVID-19 vaccine will be approved within 18 months
How quickly to life sciences professionals predict a COVID-19 vaccine will be approved and what are the main obstacles? We explore.
The biggest breakthroughs in life sciences the last 10 years
CRISPR, CAR-T, immunotherapies, genome sequencing, AI - what is the biggest breakthrough in the life sciences in the last 10 years?
Strategies to Innovate the Production of Next Generation Bioconjugates
From developing ADCs to tumor-targeting, this whitepaper reviews the latest common challenges and novel strategies for producing bioconjugates.
Diversity in the life sciences workplace: Implementing a leading corporate culture for innovation - WHITEPAPER
This paper looks at how to foster racial, gender, geographical, neuro and cognitive diversity in the life sciences to achieve an inclusive culture built for innovation.
REPORT: Diversity, Inclusion and Sustainability in the Global Life Sciences Industry 2020
Diversity and Inclusion in Life Sciences 2020: Research analysis of how life sciences professionals around the world view representation of women and minorities in the industry, plus the importance of sustainability.
Innovating CMC for Oligonucleotide and Peptide Therapeutics
In a new ebook, we look at ways to optimize chemistry manufacturing and controls for oligonucleotide and peptide therapeutics.
Looking to 2030 Report: The Future of the Global Life Sciences and Pharma Industry
This exclusive report looks at predictions for how the global life sciences and pharma industry will change over the coming decade.
COVID-19 Report: The Response to and Impacts on the Global Life Sciences Industry
COVID-19 Report: How is the life sciences industry developing a vaccine, treatment and testing for COVID-19 and what impact is it having on supply chain?
Life Sciences in 2030 Survey: Complete to win a 2-day conference pass
We are a conducting a huge survey of life sciences professionals around the world on how the industry will look by 2030. Complete it here to get early access to the final report.
Partnering in the oligonucleotide and peptide therapeutics industry - WHITEPAPER
This whitepaper looks at the partnering challenges and opportunities facing the peptide and oligonucleotide therapeutics industry, using a number of case studies.
Manufacturing oligonucleotides: addressing safety and delivery challenges
We explore ways to tackle the main challenges in designing control strategies for oligonucleotide therapeutics.
Regulatory challenges and strategies for oligonucleotide, peptide and mRNA therapeutics - WHITEPAPER
We explore the regulatory challenges and successful approval strategies for oligonucleotide, peptide and mRNA therapeutics.
What is an oligonucleotide?
What is an oligonucleotide? Discover the different oligo classes and the future of oligonucleotide therapies.